Search

Your search keyword '"Beelen, Dietrich"' showing total 1,655 results
Start Over Author "Beelen, Dietrich"
1,655 results on '"Beelen, Dietrich"'

101. Impact of CMV reactivation on relapse of acute myeloid leukemia after HCT is dependent on disease stage and ATG

Author

Turki, Amin T., primary, Tsachakis-Mück, Nikolaos, additional, Leserer, Saskia, additional, Crivello, Pietro, additional, Liebregts, Tobias, additional, Betke, Luisa, additional, Alashkar, Ferras, additional, Leimkühler, Nils B., additional, Trilling, Mirko, additional, Fleischhauer, Katharina, additional, and Beelen, Dietrich W., additional

Published
2021
Full Text
View/download PDF

102. Correction to: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

Author

Schetelig, Johannes, primary, Chevallier, Patrice, additional, van Gelder, Michel, additional, Hoek, Jennifer, additional, Hermine, Olivier, additional, Chakraverty, Ronjon, additional, Browne, Paul, additional, Milpied, Noel, additional, Malagola, Michele, additional, Socié, Gerard, additional, Delgado, Julio, additional, Deconinck, Eric, additional, Damaj, Ghandi, additional, Maury, Sebastian, additional, Beelen, Dietrich, additional, Quoc, Stéphanie Nguyen, additional, Shankara, Paneesha, additional, Brecht, Arne, additional, Mayer, Jiri, additional, Hunault-Berger, Mathilde, additional, Bittenbring, Jörg, additional, Thieblemont, Catherine, additional, Lepretre, Stéphane, additional, Baldauf, Henning, additional, de Wreede, Liesbeth C., additional, Tournilhac, Olivier, additional, Yakoub-Agha, Ibrahim, additional, Kröger, Nicolaus, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

103. Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis

Author

Dreger, Peter, primary, Schubert, Maria-Luisa, additional, Holtick, Udo, additional, Subklewe, Marion, additional, Bastian, von Tresckow, additional, Ayuk, Francis A., additional, Wagner, Eva Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Borchmann, Peter, additional, Rejeski, Kai, additional, Hanoun, Christine, additional, Lengerke, Claudia, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Kröger, Nicolaus, additional, and Bethge, Wolfgang A, additional

Published
2021
Full Text
View/download PDF

104. Allogeneic Stem Cell Transplantation in Patients Aged ≥70 Years: Epidemiology, Outcomes, and Risk Factors Based on the German Registry for Stem Cell Transplantation (DRST)

Author

Weller, Jan Frederic, primary, Kaufmann, Louisa, additional, Lengerke, Claudia, additional, Finke, Jürgen, additional, Schetelig, Johannes, additional, Platzbecker, Uwe, additional, Einsele, Hermann, additional, Beelen, Dietrich W., additional, Faul, Christoph, additional, Stelljes, Matthias, additional, Dreger, Peter, additional, Blau, Igor Wolfgang, additional, Wulf, Gerald, additional, Tischer, Johanna, additional, Scheid, Christof, additional, Elmaagacli, Ahmet, additional, Neidlinger, Helga, additional, Frank, Sandra, additional, Bornhäuser, Martin, additional, Bethge, Wolfgang A, additional, Fleischhauer, Katharina, additional, Kröger, Nicolaus, additional, and Christopeit, Maximilian, additional

Published
2021
Full Text
View/download PDF

105. Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Author

Bornhaeuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Rollig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Haenel, Mathias, additional, Mueller, Lutz Peter, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich W., additional, Roesler, Wolf, additional, Schaefer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stoelzel, Friedrich, additional, Alakel, Nael, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2021
Full Text
View/download PDF

106. Reduced Intensity Stem Cell Transplantation for Accelerated-Phase Myelofibrosis

Author

Gagelmann, Nico, primary, Badbaran, Anita, additional, Ditschkowski, Markus, additional, Panagiota, Victoria, additional, Cassinat, Bruno, additional, Heuser, Michael, additional, Thol, Felicitas, additional, Wolschke, Christine, additional, Salit, Rachel B., additional, Robin, Marie, additional, Beelen, Dietrich W., additional, Scott, Bart L., additional, and Kroeger, Nicolaus, additional

Published
2021
Full Text
View/download PDF

107. Standard of Care CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Does Bridging Efficacy Matter? a German GLA/DRST Real World Analysis

Author

Bethge, Wolfgang A, primary, Martus, Peter, additional, Schmitt, Michael, additional, Holtick, Udo, additional, Borchmann, Peter, additional, Subklewe, Marion, additional, Rejeski, Kai, additional, von Tresckow, Bastian, additional, Ayuk, Francis A., additional, Kroeger, Nicolaus, additional, Wagner-Drouet, Eva-Maria, additional, Wulf, Gerald, additional, Marks, Reinhard, additional, Penack, Olaf, additional, Schnetzke, Ulf, additional, Koenecke, Christian, additional, Von Bonin, Malte, additional, Stelljes, Matthias, additional, Glass, Bertram, additional, Baldus, Claudia D., additional, Vucinic, Vladan, additional, Mougiakakos, Dimitrios, additional, Topp, Max, additional, Wolff, Daniel, additional, Schroers, Roland, additional, Thomas, Simone, additional, Beelen, Dietrich W., additional, Lengerke, Claudia, additional, and Dreger, Peter, additional

Published
2021
Full Text
View/download PDF

108. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study)

Author

Kröger, Nicolaus, primary, Sockel, Katja, additional, Wolschke, Christine, additional, Bethge, Wolfgang, additional, Schlenk, Richard F., additional, Wolf, Dominik, additional, Stadler, Michael, additional, Kobbe, Guido, additional, Wulf, Gerald, additional, Bug, Gesine, additional, Schäfer-Eckart, Kerstin, additional, Scheid, Christof, additional, Nolte, Florian, additional, Krönke, Jan, additional, Stelljes, Matthias, additional, Beelen, Dietrich, additional, Heinzelmann, Marion, additional, Haase, Detlef, additional, Buchner, Hannes, additional, Bleckert, Gabriele, additional, Giagounidis, Aristoteles, additional, and Platzbecker, Uwe, additional

Published
2021
Full Text
View/download PDF

109. Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival

Author

Kordelas, Lambros, Buttkereit, Ulrike, Heinemann, Falko M., Horn, Peter A., Giebel, Bernd, Beelen, Dietrich W., Reinhardt, H. Christian, and Rebmann, Vera

Subjects
Adult, Male, Time Factors, inhibitory co-receptor, Immunology, Programmed Cell Death 1 Receptor, Medizin, Down-Regulation, Graft vs Host Disease, Medizinische Fakultät » Universitätsklinikum Essen » Institut für Transfusionsmedizin, soluble PD-1, Risk Assessment, Severity of Illness Index, Young Adult, Predictive Value of Tests, Risk Factors, immune system diseases, PD-1, graft-versus-host disease, Humans, Transplantation, Homologous, Prospective Studies, ddc:610, allogeneic hematopoietic stem cell transplantation, immune checkpoint, Original Research, Aged, Hematopoietic Stem Cell Transplantation, Middle Aged, RC581-607, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Hämatologie und Stammzelltransplantation, Treatment Outcome, surgical procedures, operative, Case-Control Studies, Hematologic Neoplasms, Female, GvHD biomarker, Immunologic diseases. Allergy, Biomarkers
Abstract

Programmed cell death protein-1 (PD-1) is an inhibitory co-receptor required for regulating immune responsiveness and maintaining immune homeostasis. As PD-1 can be released as bioactive soluble molecule, we investigated the clinical significance of soluble PD-1 (sPD-1) after allogeneic hematopoietic stem cell transplantation (HSCT) regarding graft-versus-host disease (GvHD), relapse, and overall survival (OS) in a mono-centric cohort of 82 patients. Compared to pre-HSCT and to healthy controls, post-HSCT sPD-1 plasma levels were significantly increased during an observation time of three months. Univariate analysis revealed that low sPD-1 plasma levels at month one, two or three post HSCT were associated with acute GvHD grade III-IV, the onset of moderate/severe chronic GvHD (cGvHD) and inferior OS, DFS, and TRM, respectively. No relationship was detected to relapse rates. sPD-1 plasma levels were significantly increased in ATG-treated patients compared to ATG-untreated patients. Multivariate analysis revealed that a low sPD-1 plasma levels status at one or two month(s) after HSCT is an independent indicator for inferior OS, DFS, or TRM. A low sPD-1 plasma levels status at month three post HSCT is predictive for the onset of moderate/severe cGvHD. Thus, our study pinpoints the soluble inhibitory co-receptor PD-1 as a promising candidate molecule for the prediction of clinical HSCT outcome. OA Förderung 2021

Published
2021

110. Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

Author

Pfirrmann, Markus, Saussele, Susanne, Hochhaus, Andreas, Reiter, Andreas, Berger, Ute, Hossfeld, Dieter K., Nerl, Christoph, Scheid, Christof, Spiekermann, Karsten, Mayer, Jiri, Hellmann, Andrzej, Lechner, Klaus, Falge, Christiane, Sayer, Herbert G., Bunjes, Donald, Ganser, Arnold, Beelen, Dietrich W., Baldomero, Helen, Schanz, Urs, Heimpel, Hermann, Kolb, Hans-Jochem, Hasford, Joerg, Gratwohl, Alois, Hehlmann, Rüdiger, and for the Schweizerische Arbeitsgemeinschaft für Klinische Forschung (SAKK) and the German CML Study Group

Published
2014
Full Text
View/download PDF

111. Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Eder, Sandra, Labopin, Myriam, Arcese, William, Or, Reuven, Majolino, Ignazio, Bacigalupo, Andrea, de Rosa, Gennaro, Volin, Liisa, Beelen, Dietrich, Veelken, Hendrik, Schaap, Nicolaas P. M., Kuball, Jurgen, Cornelissen, Jan, Nagler, Arnon, and Mohty, Mohamad

Published
2016
Full Text
View/download PDF

113. Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation

Author

Symeonidis, Argiris, van Biezen, Anja, de Wreede, Liesbeth, Piciocchi, Alfonso, Finke, Juergen, Beelen, Dietrich, Bornhäuser, Martin, Cornelissen, Jan, Volin, Liisa, Mufti, Ghulam, Chalandon, Yves, Ganser, Arnold, Bruno, Benedetto, Niederwieser, Dietger, Kobbe, Guido, Schwerdtfeger, Rainer, de Witte, Theo, Robin, Marie, and Kröger, Nicolaus

Published
2015
Full Text
View/download PDF

114. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Author

Dreger, Peter, Döhner, Hartmut, Ritgen, Matthias, Böttcher, Sebastian, Busch, Raymonde, Dietrich, Sascha, Bunjes, Donald, Cohen, Sandra, Schubert, Jörg, Hegenbart, Ute, Beelen, Dietrich, Zeis, Matthias, Stadler, Michael, Hasenkamp, Justin, Uharek, Lutz, Scheid, Christof, Humpe, Andreas, Zenz, Thorsten, Winkler, Dirk, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, and Stilgenbauer, Stephan

Published
2010
Full Text
View/download PDF

116. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV

Author

Saussele, Susanne, Lauseker, Michael, Gratwohl, Alois, Beelen, Dietrich W., Bunjes, Donald, Schwerdtfeger, Rainer, Kolb, Hans-Jochem, Ho, Anthony D., Falge, Christiane, Holler, Ernst, Schlimok, Günter, Zander, Axel R., Arnold, Renate, Kanz, Lothar, Dengler, Robert, Haferlach, Claudia, Schlegelberger, Brigitte, Pfirrmann, Markus, Müller, Martin C., Schnittger, Susanne, Leitner, Armin, Pletsch, Nadine, Hochhaus, Andreas, Hasford, Joerg, Hehlmann, Rüdiger, and for the German CML Study Group

Published
2010
Full Text
View/download PDF

119. Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study

Author

Kroeger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegor, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Therese, Beguin, Yves, Finke, Juergen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, Dem Borne, Peter, Nicolaas Schaap, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yegin, Zeynep Arzu, Hayden, Patrick, Mclornan, Donal, and Yakoub-Agha, Ibrahim

Published
2021

122. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced‐intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT

Author

Shimoni, Avichai, primary, Robin, Marie, additional, Iacobelli, Simona, additional, Beelen, Dietrich, additional, Mufti, Ghulam J., additional, Ciceri, Fabio, additional, Bethge, Wolfgang, additional, Volin, Liisa, additional, Blaise, Didier, additional, Ganser, Arnold, additional, Luft, Thomas, additional, Chevallier, Patrice, additional, Schwerdtfeger, Rainer, additional, Koster, Linda, additional, de Witte, Theo, additional, Kröger, Nicolaus, additional, Nagler, Arnon, additional, and Yakoub-Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

123. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry

Author

Hernández‐Boluda, Juan‐Carlos, primary, Pereira, Arturo, additional, Kröger, Nicolaus, additional, Cornelissen, Jan J., additional, Finke, Jürgen, additional, Beelen, Dietrich, additional, de Witte, Moniek, additional, Wilson, Keith, additional, Platzbecker, Uwe, additional, Sengeloev, Henrik, additional, Blaise, Didier, additional, Einsele, Hermann, additional, Sockel, Katja, additional, Krüger, William, additional, Lenhoff, Stig, additional, Salaroli, Adriano, additional, Martin, Hans, additional, García‐Gutiérrez, Valentín, additional, Pavone, Vicenzo, additional, Alvarez‐Larrán, Alberto, additional, Raya, José‐María, additional, Zinger, Nienke, additional, Gras, Luuk, additional, Hayden, Patrick, additional, Czerw, Tomasz, additional, P. McLornan, Donal, additional, and Yakoub‐Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

124. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG

Author

Braess, Jan, Spiekermann, Karsten, Staib, Peter, Grüneisen, Andreas, Wörmann, Bernhard, Ludwig, Wolf-Dieter, Serve, Hubert, Reichle, Albrecht, Peceny, Rudolf, Oruzio, Daniel, Schmid, Christoph, Schiel, Xaver, Hentrich, Marcus, Sauerland, Christina, Unterhalt, Michael, Fiegl, Michael, Kern, Wolfgang, Buske, Christian, Bohlander, Stefan, Heinecke, Achim, Baurmann, Herrad, Beelen, Dietrich W., Berdel, Wolfgang E., Büchner, Thomas, and Hiddemann, Wolfgang

Published
2009
Full Text
View/download PDF

125. The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia : On behalf of the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT)

Author

Poiani, Monica, Labopin, Myriam, Battipaglia, Giorgia, Beelen, Dietrich, Tischer, Johanna, Finke, Jürgen, Brecht, Arne, Forcade, Edouard, Ganser, Arnold, Passweg, Jakob R., Labussiere-Wallet, Helene, Yakoub-Agha, Ibrahim, Schäfer-Eckart, Kerstin, Kroeger, Nicolaus, Guffroy, Blandine, Ruggeri, Annalisa, Esteve, Jordi, Nagler, Arnon, and Mohty, Mohamad

Subjects
Medizin
Published
2021

128. Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey (Bone Marrow Transplantation, (2020), 55, 12, (2335-2338), 10.1038/s41409-020-0946-x)

Author

Sellner, Leopold, Schetelig, Johannes, Koster, Linda, Choi, Goda, Blaise, Didier, Beelen, Dietrich, Schianca, Fabrizio Carnevale, Passweg, Jakob, Schanz, Urs, Gyan, Emmanuel, Sora, Federica, Kröger, Nicolaus, Wulf, Gerald. G., Van Gorkom, Gwendolyn, Mayer, Jiri, Orvain, Corentin, Bourhis, Jean Henri, Jindra, Pavel, Potter, Victoria, Zallio, Francesco, Vandenberghe, Elisabeth, Robinson, Stephen, Hayden, Patrick J., Yakoub-Agha, Ibrahim, Montoto, Silvia, and Dreger, Peter

Subjects
Medizin
Abstract

The article “Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey”, written by Leopold Sellner, Johannes Schetelig, Linda Koster, Goda Choi, Didier Blaise, Dietrich Beelen, Fabrizio Carnevale Schianca, Jakob Passweg, Urs Schanz, Emmanuel Gyan, Federica Sora, Nicolaus Kröger, Gerald. G. Wulf, Gwendolyn Van Gorkom, Jiri Mayer, Corentin Orvain, Jean Henri Bourhis, Pavel Jindra, Victoria Potter, Francesco Zallio, Elisabeth Vandenberghe, Stephen Robinson, Patrick J. Hayden, Ibrahim Yakoub-Agha, Silvia Montoto, Peter Dreger, on behalf of the European Society for Blood and Marrow Transplantation Lymphoma and Chronic Malignancies Working Parties, was originally published Online First without Open Access. After publication in volume 55, issue 12, page 2335–2338, the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2020 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ licenses/by/4.0. Open access funding is enabled and organized by Projekt DEAL. Korrektur zu: 10.1038/s41409-020-0946-x

Published
2021

130. Allogeneic Hematopoietic Stem Cell Transplantation for BCR/ABL1-Negative Myeloproliferative Neoplasms in Children - Retrospective Report on Behalf of I-BFM SCT Committee and EBMT Pediatric Diseases WP

Author

Patrick, Katharine, Gruhn, Bernd, Corbacioglu, Selim, Kupesiz, Alphan, Balduzzi, Adriana, Al-Seraihy, Amal, Wynn, Robert, Veys, Paul, Stepensky, Polina, Robinson, Stephen, Locatelli, Franco, Dalissier, Arnaud, Galimard, Jacques-Emmanuel, Wachowiak, Jacek, Tbakhi, Abdelghani, Diaz, Miguel Angel, Socie, Gerard, Sedlacek, Petr, Abboud, Miguel, Beelen, Dietrich, Krivan, Gergely, ÜNAL, ALİ, Bodova, Ivana, Freycon, Claire, Dalle, Jean-Hugues, Jubert, Charlotte, Ferster, Alina, Ifversen, Marianne, and Hamladji, Rose-Marie

Published
2020

136. Evaluation of the drug‐drug interaction potential of treosulfan using a physiologically‐based pharmacokinetic modelling approach.

Author

Schaller, Stephan, Martins, Frederico S., Balazki, Pavel, Böhm, Sonja, Baumgart, Joachim, Hilger, Ralf A., Beelen, Dietrich W., Hemmelmann, Claudia, and Ring, Arne

Subjects
DRUG interactions, PHARMACOKINETICS, CYTOCHROME P-450, OMEPRAZOLE, CYTOCHROME P-450 CYP3A, ISOENZYMES
Abstract

Aims: The aim of this work is the development of a mechanistic physiologically‐based pharmacokinetic (PBPK) model using in vitro to in vivo extrapolation to conduct a drug‐drug interaction (DDI) assessment of treosulfan against two cytochrome p450 (CYP) isoenzymes and P‐glycoprotein (P‐gp) substrates. Methods: A PBPK model for treosulfan was developed de novo based on literature and unpublished clinical data. The PBPK DDI analysis was conducted using the U.S. Food and Drug Administration (FDA) DDI index drugs (probe substrates) midazolam, omeprazole and digoxin for CYP3A4, CYP2C19 and P‐gp, respectively. Qualified and documented PBPK models of the probe substrates have been adopted from an open‐source online model database. Results: The PBPK model for treosulfan, based on both in vitro and in vivo data, was able to predict the plasma concentration‐time profiles and exposure levels of treosulfan applied for a standard conditioning treatment. Medium and low potentials for DDI on CYP3A4 (maximum area under the concentration‐time curve ratio (AUCRmax = 2.23) and CYP2C19 (AUCRmax = 1.6) were predicted, respectively, using probe substrates midazolam and omeprazole. Treosulfan was not predicted to cause a DDI on P‐gp. Conclusion: Medicinal products with a narrow therapeutic index (eg, digoxin) that are substrates for CYP3A4, CYP2C19 or P‐gp should not be given during treatment with treosulfan. However, considering the comprehensive treosulfan‐based conditioning treatment schedule and the respective pharmacokinetic properties of the concomitantly used drugs (eg, half‐life), the potential for interaction on all evaluated mechanisms would be low (AUCR < 1.25), if concomitantly administered drugs are dosed either 2 hours before or 8 hours after the 2‐hour intravenous infusion of treosulfan. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

137. MRD Status Impact on Secondary Acute Myeloid Leukemia Outcomes after Allogeneic Hematopoietic Cell Transplantation. A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Maffini, Enrico, primary, Labopin, Myriam, additional, Beelen, Dietrich Wilhelm, additional, Kroeger, Nicolaus, additional, Arat, Mutlu, additional, Wilson, Keith M.O., additional, Bay, Jacques-Olivier, additional, Ganser, Arnold, additional, Martin, Hans, additional, Passweg, Jakob, additional, Carpenter, Ben, additional, Yakoub-Agha, Ibrahim, additional, Porras, Rocio Parody, additional, Wagner, Eva Maria, additional, Lanza, Francesco, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2021
Full Text
View/download PDF

139. Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT

Author

Nabergoj, Mitja, primary, Mauff, Katya, additional, Beelen, Dietrich, additional, Ganser, Arnold, additional, Krogër, Nicolaus, additional, Stölzel, Friedrich, additional, Finke, Jürgen, additional, Passweg, Jakob, additional, Cornelissen, Jan, additional, Schub, Natalie, additional, Veelken, Joan Hendrik, additional, Beguin, Yves, additional, Wilson, Keith, additional, Zuckerman, Tsila, additional, Hunault-Berger, Mathilde, additional, Lioure, Bruno, additional, Parody, Rocio, additional, Turlure, Pascal, additional, Kerre, Tessa, additional, Koster, Linda, additional, Hayden, Patrick J., additional, Onida, Francesco, additional, Scheid, Christof, additional, Chalandon, Yves, additional, Robin, Marie, additional, and Yakoub-Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

140. Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia

Author

Gagelmann, Nico, primary, Bogdanov, Rashit, additional, Stölzel, Friedrich, additional, Rautenberg, Christina, additional, Panagiota, Victoria, additional, Becker, Heiko, additional, Radujkovic, Aleksandar, additional, Luft, Thomas, additional, Christopeit, Maximilian, additional, Finke, Jürgen, additional, Platzbecker, Uwe, additional, Ditschkowski, Markus, additional, Schroeder, Thomas, additional, Koldehoff, Michael, additional, Heuser, Michael, additional, Kobbe, Guido, additional, Beelen, Dietrich W., additional, Germing, Ulrich, additional, and Kröger, Nicolaus, additional

Published
2021
Full Text
View/download PDF

141. Impact of Mutation Profile in Chronic Myelomonocytic Leukemia undergoing Allogeneic Hematopoietic Cell Transplantation

Author

Gagelmann, Nico, Badbaran, Anita, Bogdanov, Rashit, Stoelzel, Friedrich, Rautenberg, Christina, Nibourel, Olivier, Becker, Heiko, Radujkovic, Aleksandar, Dreger, Peter, Christopeit, Maximilian, Finke, Juergen, Platzbecker, Uwe, Koldehoff, Michael, Ditschkowski, Markus, Beelen, Dietrich, Robin, Marie, and Kröger, Nicolaus

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2020

142. Modifikation der total nodalen Bestrahlung (TNI) als Teil der Konditionierung vor allogener Stammzelltransplantation (aSZT) bei hämatologischen Erkrankungen mittels helikaler Tomotherapie anhand einer retrospektiven Kohorte

Author

Gauler, Thomas, Ottinger, Hellmut, Basu, Oliver, Pöttgen, Christoph, Guberina, Marko, Guberina, N., Trenschel, Rudolf, Reinhardt, Dirk, Beelen, Dietrich, and Stuschke, Martin

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster Abstract

Published
2020

144. Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival

Author

Kordelas, Lambros, Schwich, Esther, Lindemann, Monika, Heinemann, Falko M., Buttkereit, Ulrike, Horn, Peter, Beelen, Dietrich, and Rebmann, Vera

Subjects
Adult, Male, lcsh:Immunologic diseases. Allergy, Genotype, HLA-E, T-Lymphocytes, Immunology, HLA-G, Medizin, Graft vs Host Disease, chemical and pharmacologic phenomena, Medizinische Fakultät » Universitätsklinikum Essen » Institut für Transfusionsmedizin, Young Adult, immune system diseases, graft-versus-host disease, Humans, Transplantation, Homologous, ddc:610, allogeneic hematopoietic stem cell transplantation, Medizinische Fakultät » Universitätsklinikum Essen » Klinik für Knochenmarktransplantation, Aged, Original Research, Histocompatibility Antigens Class I, Hematopoietic Stem Cell Transplantation, Middle Aged, HLA, surgical procedures, operative, Female, GvHD biomarker, lcsh:RC581-607
Abstract

HLA-E is a member of the non-classical HLA molecules and by interaction with activating or inhibitory receptors of NK and T cells, HLA-E can lead to immune activation or suppression context-dependently. Recently, the non-classical HLA molecules gain more attention in the setting of allogeneic hematopoietic stem cell transplantation (HSCT). Most studies so far have focused on the two most frequent genotypes (HLA-E*01:01 and HLA-E*01:03) and investigated their potential association with clinical endpoints of HSCT, like graft-versus-host disease (GvHD), relapse, and overall survival (OS). However, these studies have produced inconsistent results regarding the role of HLA-E and the clinical endpoints after HSCT. We therefore here investigate the amount of soluble HLA-E (sHLA-E) in patients following HSCT and relate this to the clinical endpoints after HSCT. In univariate analysis, we observe a significant association of reduced levels of sHLA-E with severe acute GvHD, extended chronic GvHD and with inferior OS. Using receiver operating characteristic analyses specific thresholds obtained 1, 2, or 3 month(s) after HSCT were identified being indicative for severe acute GvHD, extended chronic GvHD, or inferior OS. In sub-group analyses, this effect can be confirmed in patients not treated with ATG, but is derogated in ATG-treated patients. Notably, we could not detect any association of the course of sHLA-E levels post-HSCT with the three most frequent HLA-E genotypes (HLA-E*01:03/*01:03, HLA-E*01:01/*01:01, HLA-E*01:01/*01:03). However, with regard to 5-year-OS there was an association of HLA-E*01:03 homozygosity with inferior OS. Taking ATG-treatment, recipient and donor HLA-E genotypes into consideration among other well-known risk factors, the sHLA-E status was found as an independent predictor for the development of extended cGvHD and inferior OS following HSCT irrespective of the sHLA-E thresholds. These findings shed some light on the possible impact of reduced sHLA-E levels after HSCT on GvHD and OS. Thus, sHLA-E appears to be a novel promising candidate for the prediction of clinical HSCT outcome with regards to extended cGvHD and OS. OA Förderung 2020

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results